MedPath

BIOKAD, AO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website

Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-03-20
Last Posted Date
2021-11-05
Lead Sponsor
Biocad
Target Recruit Count
94
Registration Number
NCT02395055
Locations
🇷🇺

LLC BioEk, Saint-Petersburg, Russian Federation

First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: humanized monoclonal antibody against human IL-17
First Posted Date
2015-03-05
Last Posted Date
2021-03-03
Lead Sponsor
Biocad
Target Recruit Count
22
Registration Number
NCT02380287

A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries

Phase 3
Completed
Conditions
Deep Vein Thrombosis
Interventions
Drug: Sodium Enoxaparine
First Posted Date
2015-02-23
Last Posted Date
2016-10-24
Lead Sponsor
Biocad
Target Recruit Count
124
Registration Number
NCT02368314
Locations
🇷🇺

Railroad Clinical Hospital at the station Chelyabinsk, Chelyabinsk, Russian Federation

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-02-10
Last Posted Date
2017-04-10
Lead Sponsor
Biocad
Target Recruit Count
60
Registration Number
NCT02359877
Locations
🇷🇺

OOO "BioEk", Saint-Petersburg, Russian Federation

Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

Phase 1
Completed
Conditions
Ankylosing Spondylitis
Interventions
First Posted Date
2015-02-10
Last Posted Date
2016-06-08
Lead Sponsor
Biocad
Target Recruit Count
90
Registration Number
NCT02359903
Locations
🇧🇾

Vitebsk Regional Clinical Hospital, Vitebsk, Belarus

🇷🇺

Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation

🇷🇺

Research Institute of Rheumotology, Moscow, Russian Federation

and more 3 locations

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Phase 3
Completed
Conditions
Chemotherapy-induced Neutropenia
First Posted Date
2014-04-04
Last Posted Date
2016-10-24
Lead Sponsor
Biocad
Target Recruit Count
135
Registration Number
NCT02104830
Locations
🇷🇺

Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk, Russian Federation

🇷🇺

Clinical Hospital at Chelyabinsk Railway Station, Chelyabinsk, Russian Federation

🇷🇺

State public health institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation

and more 10 locations

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Phase 3
Completed
Conditions
Hepatitis C
Hepatitis C/ Human Immunodeficiency Virus Coinfection
Hepatitis
Interventions
First Posted Date
2014-04-03
Last Posted Date
2018-08-09
Lead Sponsor
Biocad
Target Recruit Count
140
Registration Number
NCT02103439
Locations
🇷🇺

State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan, Kazan, Republic Of Tatarstan, Russian Federation

🇷🇺

State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases", Nizhny Novgorod, Russian Federation

🇷🇺

State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department, Sankt-Petersburg, Russian Federation

and more 3 locations

Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Phase 3
Withdrawn
Conditions
Wet Age-related Macular Degeneration
Interventions
First Posted Date
2014-01-15
Last Posted Date
2016-03-31
Lead Sponsor
Biocad
Registration Number
NCT02036723
Locations
🇧🇷

Universidade Estadual de Londrina, Londrina, Parana, Brazil

🇧🇷

Hospital dos Olhos do Paraná, Curitiba, Paraná, Brazil

🇧🇷

Universidade Federal de Minas Gerais Hospital das Clínicas, Belo Horizonte, Brazil

and more 10 locations

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Phase 3
Completed
Conditions
Hepatitis
Hepatitis C
Interventions
First Posted Date
2013-06-28
Last Posted Date
2018-07-16
Lead Sponsor
Biocad
Target Recruit Count
170
Registration Number
NCT01889433
Locations
🇧🇾

Gomel Regional Clinical Hospital, Gomel, Belarus

🇧🇾

Vitebsk Regional Clinical Hospital, Vitebsk, Belarus

🇮🇳

Suyash Hospital Pvt. Ltd. Opposite M.G.M Medical College A.B. Road, Indore, India

and more 16 locations

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-01-11
Last Posted Date
2016-05-04
Lead Sponsor
Biocad
Target Recruit Count
32
Registration Number
NCT01766024
Locations
🇷🇺

City Mariin Hospital, St. Petersburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath